18 September 2020 | News
TheAQS3™proA allows biopharmaceutical companies to accelerate and de-risk their drug development pipelines with ultra-sensitive measurements of minute protein structural changes
RedShift BioAnalytics, Inc. (RedShiftBio) has announced its award winning AQS3™pro, based on Microfluidic Modulation Spectroscopy (MMS) technology, is now available in India.
The US based company has appointed Spinco Biotech as exclusive Indian distributor. This partnership adds to recent distributor agreements signed in China and Japan, in response to the rapid growth in global demand for the novelAQS3™pro.
Designed specifically for protein characterization applications in the biopharmaceutical industry, the technology has already seen wide adoption in the analytical toolkit of companies developing life-saving biotherapeutics and vaccines.
The partnership with Spinco Biotech will satisfy the growing demand from the Indian biopharma industry for multi-functional, easy to use biophysical characterization tools for protein secondary structural analysis.
TheAQS3™proA allows biopharmaceutical companies to accelerate and de-risk their drug development pipelines with ultra-sensitive measurements of minute protein structural changes.
“We have observed a rapid adoption of the AQS3™pro driven by biotherapeutics development in the major producers of biopharmaceuticals globally” said Julien Bradley, CEO at RedShiftBio. “Spinco Biotech is working closely with leading Indian companies in both drug and vaccine development, and has extensive experience in introducing novel biophysical characterization technologies. The company is an ideal partner to help support and capitalize on the large market opportunity in India for the AQS 3pro.”